TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now

The Motley Fool Logo The Motley Fool By Manali Pradhan
2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now

Eli Lilly reported strong Q3 performance with 54% revenue growth and impressive diabetes/weight loss drug market share. The company is expanding its GLP-1 drug portfolio and has promising pipeline developments in multiple therapeutic areas.

Insights
TMUSL   neutral

Mentioned as a partner without specific details of direct contribution


LLY   positive

Strong financial performance, dominant market share in incretin analog market, promising drug pipeline with potential FDA approvals for oral GLP-1 drugs, and expansion in multiple therapeutic areas including oncology, neuroscience, and immunology